Birendra Sah profile picture
315 464-3835

Birendra Sah, MD, FCCP

2604 推荐最近最火的赌博软件 University Hospital
东亚当斯街750号
锡拉丘兹,纽约州13210
Birendra Sah's email address generated as an image

当前预约

Associate Professor of 医学

专业

内科医学
肺部疾病
Critical Care 医学

语言

英语
尼泊尔
北印度语

病人类型

成年人

研究兴趣

结节病

 

ASSOCIATIONS / MEMBERSHIPS

American College of Chest Physicians (ACCP)
American Thoracic Society (ATS)
Society of Critical Care 医学

教育

奖学金: SUNY 推荐最近最火的赌博软件 Medical University, 2011
住院医师: SUNY 推荐最近最火的赌博软件 Medical University, 2008
MD: B. P. Koirala Institute of Health Science, Dharan, Nepal, 2001

研究抽象

Epub 2015 10月23日.

Novel pharmacotherapy of sarcoidosis

Birendra P Sah 1信心Goyal 2Michael C . Iannuzzi 2

 

id: 26478443 doi: 10.1016/j.pharmthera.2015.10.001

 

摘要

结节病 is a multisystem granulomatous disease of unknown etiology that most commonly affects the lungs. Treatment of sarcoidosis can be challenging as it is often difficult to measure disease activity and distinguish active inflammation from fibrosis. Identifying the inflammatory mediators in sarcoidosis has led to the development and use of novel therapeutic agents. The goal of pharmacotherapy is to decrease granuloma accumulation, ameliorate symptoms and improve organ function. Systemic corticosteroids remain the first line treatment. Other immunosuppressive agents may be considered for the patients who respond poorly to corticosteroids or who experience significant adverse effects. An overview of pharmacotherapy of sarcoidosis is provided here.

关键词: Corticosteroids; Immunosuppressive agents; 肺; 结节病; Symptoms; Treatment.

 

出版物

链接到 PubMed (打开新窗口. 关闭 the PubMed window to return to this page.)